

# Leucemia Mielóide Crônica

## **Imatinibe**

Imatinibe: 400 mg/dia VO

Ref. (1)

## **Dasatinibe**

Dasatinibe: 70mg VO BID

Dasatinibe: 100mg VO MID

Ref. (2)

## **Nilotinibe**

Nilotinibe: 400mg VO BID

Ref. (3)

## **Hidroxiuréia**

Hidroxiuréia: 40 mg/kg/dia VO

Ref. (4)

1. Kantarjian H, *et al.* Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia. *NEJM*.2002;346:645-52.
2. Shah NP; Kantarjian HM; Kim DW; *et al.* Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.*J Clin Oncol.* 2008 Jul 1;26(19):3204-12.
3. Available from the US FDA website at: <[www.fda.gov/cder/foi/label/2007/022068lbl.pdf](http://www.fda.gov/cder/foi/label/2007/022068lbl.pdf)>
4. Hehlmann R, *et al.* Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. *Blood* 1994;84:4064-4077.